Refractory status epilepticus: New insights in presentation, treatment, and outcome

Sara Hocker, Eelco F M Wijdicks, Alejandro Rabinstein

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Refractory status epilepticus (RSE), defined as status epilepticus that fails to respond to the acute administration of two antiepileptic medications, occurs in approximately a third of patients with status epilepticus, and is associated with increased hospital length of stay, mortality, and functional disability. Common presentations include: (1) generalized convulsive status epilepticus or complex partial status epilepticus that continue despite initial therapies; (2) stupor or coma following a generalized convulsive or complex partial seizure; or (3) stupor or coma following brain surgery or acute brain injury. When status epilepticus continues or recurs 24 hours or more after the initiation of anesthetic therapy, or recurs on the reduction or withdrawal of anesthesia, it is termed super RSE. Published evidence on optimal management of RSE consists largely of case reports or small series. The mainstay of treatment is the administration of anesthetic agents titrated to electrographic seizure control. Adjunctive therapies include hypothermia and immunosuppression and less commonly, surgery, electrical stimulation therapies, and induction of ketosis. Patients with cardiopulmonary complications and prolonged duration of drug-induced coma tend to have worse post-treatment functional outcomes. However, significant improvement over time can occur in survivors, and thus treatment is justified even in patients who require prolonged anesthetic coma. The strongest predictors of outcome are duration of anesthetic coma, etiology, and development of cardiopulmonary complications.

Original languageEnglish (US)
Pages (from-to)163-168
Number of pages6
JournalNeurological Research
Volume35
Issue number2
DOIs
StatePublished - Jan 1 2013

Fingerprint

Status Epilepticus
Coma
Anesthetics
Stupor
Length of Stay
Seizures
Electric Stimulation Therapy
Therapeutics
Ketosis
Hypothermia
Anticonvulsants
Immunosuppression
Brain Injuries
Survivors
Anesthesia
Mortality
Brain
Pharmaceutical Preparations

Keywords

  • Critical care medicine
  • EEG
  • Medical complications
  • Status epilepticus

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Refractory status epilepticus : New insights in presentation, treatment, and outcome. / Hocker, Sara; Wijdicks, Eelco F M; Rabinstein, Alejandro.

In: Neurological Research, Vol. 35, No. 2, 01.01.2013, p. 163-168.

Research output: Contribution to journalArticle

@article{332f6356e14b47b894c413cb6df3b280,
title = "Refractory status epilepticus: New insights in presentation, treatment, and outcome",
abstract = "Refractory status epilepticus (RSE), defined as status epilepticus that fails to respond to the acute administration of two antiepileptic medications, occurs in approximately a third of patients with status epilepticus, and is associated with increased hospital length of stay, mortality, and functional disability. Common presentations include: (1) generalized convulsive status epilepticus or complex partial status epilepticus that continue despite initial therapies; (2) stupor or coma following a generalized convulsive or complex partial seizure; or (3) stupor or coma following brain surgery or acute brain injury. When status epilepticus continues or recurs 24 hours or more after the initiation of anesthetic therapy, or recurs on the reduction or withdrawal of anesthesia, it is termed super RSE. Published evidence on optimal management of RSE consists largely of case reports or small series. The mainstay of treatment is the administration of anesthetic agents titrated to electrographic seizure control. Adjunctive therapies include hypothermia and immunosuppression and less commonly, surgery, electrical stimulation therapies, and induction of ketosis. Patients with cardiopulmonary complications and prolonged duration of drug-induced coma tend to have worse post-treatment functional outcomes. However, significant improvement over time can occur in survivors, and thus treatment is justified even in patients who require prolonged anesthetic coma. The strongest predictors of outcome are duration of anesthetic coma, etiology, and development of cardiopulmonary complications.",
keywords = "Critical care medicine, EEG, Medical complications, Status epilepticus",
author = "Sara Hocker and Wijdicks, {Eelco F M} and Alejandro Rabinstein",
year = "2013",
month = "1",
day = "1",
doi = "10.1179/1743132812Y.0000000128",
language = "English (US)",
volume = "35",
pages = "163--168",
journal = "Neurological Research",
issn = "0161-6412",
publisher = "Maney Publishing",
number = "2",

}

TY - JOUR

T1 - Refractory status epilepticus

T2 - New insights in presentation, treatment, and outcome

AU - Hocker, Sara

AU - Wijdicks, Eelco F M

AU - Rabinstein, Alejandro

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Refractory status epilepticus (RSE), defined as status epilepticus that fails to respond to the acute administration of two antiepileptic medications, occurs in approximately a third of patients with status epilepticus, and is associated with increased hospital length of stay, mortality, and functional disability. Common presentations include: (1) generalized convulsive status epilepticus or complex partial status epilepticus that continue despite initial therapies; (2) stupor or coma following a generalized convulsive or complex partial seizure; or (3) stupor or coma following brain surgery or acute brain injury. When status epilepticus continues or recurs 24 hours or more after the initiation of anesthetic therapy, or recurs on the reduction or withdrawal of anesthesia, it is termed super RSE. Published evidence on optimal management of RSE consists largely of case reports or small series. The mainstay of treatment is the administration of anesthetic agents titrated to electrographic seizure control. Adjunctive therapies include hypothermia and immunosuppression and less commonly, surgery, electrical stimulation therapies, and induction of ketosis. Patients with cardiopulmonary complications and prolonged duration of drug-induced coma tend to have worse post-treatment functional outcomes. However, significant improvement over time can occur in survivors, and thus treatment is justified even in patients who require prolonged anesthetic coma. The strongest predictors of outcome are duration of anesthetic coma, etiology, and development of cardiopulmonary complications.

AB - Refractory status epilepticus (RSE), defined as status epilepticus that fails to respond to the acute administration of two antiepileptic medications, occurs in approximately a third of patients with status epilepticus, and is associated with increased hospital length of stay, mortality, and functional disability. Common presentations include: (1) generalized convulsive status epilepticus or complex partial status epilepticus that continue despite initial therapies; (2) stupor or coma following a generalized convulsive or complex partial seizure; or (3) stupor or coma following brain surgery or acute brain injury. When status epilepticus continues or recurs 24 hours or more after the initiation of anesthetic therapy, or recurs on the reduction or withdrawal of anesthesia, it is termed super RSE. Published evidence on optimal management of RSE consists largely of case reports or small series. The mainstay of treatment is the administration of anesthetic agents titrated to electrographic seizure control. Adjunctive therapies include hypothermia and immunosuppression and less commonly, surgery, electrical stimulation therapies, and induction of ketosis. Patients with cardiopulmonary complications and prolonged duration of drug-induced coma tend to have worse post-treatment functional outcomes. However, significant improvement over time can occur in survivors, and thus treatment is justified even in patients who require prolonged anesthetic coma. The strongest predictors of outcome are duration of anesthetic coma, etiology, and development of cardiopulmonary complications.

KW - Critical care medicine

KW - EEG

KW - Medical complications

KW - Status epilepticus

UR - http://www.scopus.com/inward/record.url?scp=84874596247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874596247&partnerID=8YFLogxK

U2 - 10.1179/1743132812Y.0000000128

DO - 10.1179/1743132812Y.0000000128

M3 - Article

C2 - 23336320

AN - SCOPUS:84874596247

VL - 35

SP - 163

EP - 168

JO - Neurological Research

JF - Neurological Research

SN - 0161-6412

IS - 2

ER -